Wagner W, Hartlapp J, Esser E, Christoph B, Krech R, Alfrink M
Paracelsus-Strahlenklinik, D-49076 Osnabruck, Germany.
Oncol Rep. 1998 Sep-Oct;5(5):1251-3. doi: 10.3892/or.5.5.1251.
We analysed the files of 52 patients with advanced head and neck tumors who were treated in a pilot phase. The therapy consisted of two courses of induction chemotherapy with ifosfamide and cisplatin followed by hyperfractionated-accelerated radiotherapy with a total dose of only 30 Gy. Surgery was performed within the following 7 days with tumor resection and neck dissection. Histologically we found in 50% of the specimens total necrosis of the tumor. The median survival time is calculated to be 22 months. The median follow-up time thus far is 36 months. Hence, therapy results are comparable to other therapy schedules. But side effects, especially late side effects had become minor. Therefore, our therapy regime results in augmentation of the quality of life of these patients.
我们分析了在试点阶段接受治疗的52例晚期头颈部肿瘤患者的病历。治疗方案包括两个疗程的异环磷酰胺和顺铂诱导化疗，随后进行总剂量仅30 Gy的超分割加速放疗。在接下来的7天内进行手术，切除肿瘤并进行颈部清扫。组织学检查发现，50%的标本中肿瘤完全坏死。计算得出中位生存时间为22个月。迄今为止的中位随访时间为36个月。因此，治疗结果与其他治疗方案相当。但副作用，尤其是晚期副作用已变得轻微。所以，我们的治疗方案提高了这些患者的生活质量。
